Hemab Therapeutics Holdings priced an upsized IPO of 16.75 million shares at $18 per share, targeting gross proceeds of $301.5 million with additional potential proceeds from overallotment. The offering comes as the company plans to trade on Nasdaq under the ticker COAG. Hemab is focused on coagulation disorders including Glanzmann thrombasthenia and von Willebrand disease, and the financing is expected to fund development and commercialization planning. The deal adds to the 2026 IPO resurgence highlighted by multiple biotech listings and reflects continuing demand for specialized hematology franchises in public markets.